公开(公告)号：US20200331959A1

公开(公告)日：2020-10-22

申请号：US16923154

申请日：2020-07-08

Applicant: Pfizer Inc.

Inventor： Mingming Han ,  Rajesh Kumar Kainthan ,  Jin-Hwan Kim ,  Avvari Krishna Prasad

IPC: C07K1/107 ,  C07K14/34 ,  C07K14/22 ,  C07K14/315 ,  A61K39/095 ,  A61K39/09 ,  A61K47/64 ,  C07H3/06

Abstract: The present disclosure relates generally to methods of preparing glycoconjugates containing a saccharide conjugated to a carrier protein by use of stable nitroxyl radical related agent/oxidant as an oxidizing agent, to immunogenic compositions comprising such glycoconjugates, and to methods for the use of such glycoconjugates and immunogenic compositions.

公开(公告)号：US10668164B2

公开(公告)日：2020-06-02

申请号：US15118038

申请日：2015-02-06

Applicant: PFIZER INC.

Inventor： Jianxin Gu ,  Rajesh Kumar Kainthan ,  Jin-Hwan Kim ,  Avvari Krishna Prasad ,  Yu-Ying Yang

IPC: A61K47/64 ,  A61K39/09 ,  A61K39/00

Abstract: The present invention relates generally to glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a spacer containing ((2-oxoethyl)thio)). In an aspect the invention provides oxo-eT linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a ((2-oxoethyl)thio) spacer having the formula (I): (I) wherein: A is a group (C═X)m wherein X is S or O and m is 0 or 1; B is a bond, O, or CH2; and when m is 0, B can also be (C═O); R is a C2-C16 alkylene, C2-C16 heteroalkylene, NH—C(═O)—C2-C16 alkylene, or NH—C(═O)—C2-C16 heteroalkylene, wherein said alkylene and heteroalkylene are optionally substituted by 1, 2 or 3 groups independently selected from COOR′ where R′ is selected from H, methyl, ethyl or propyl. The invention further relates to immunogenic compositions comprising such glycoconjugates, and to methods for the preparation and use of such glycoconjugates and immunogenic compositions.

公开(公告)号：US20190330265A1

公开(公告)日：2019-10-31

申请号：US16505757

申请日：2019-07-09

Applicant: Pfizer Inc.

Inventor： Mingming Han ,  Rajesh Kumar Kainthan ,  Jin-Hwan Kim ,  Avvari Krishna Prasad

IPC: C07K1/107 ,  A61K39/09 ,  C07H3/06 ,  A61K47/64 ,  C07K14/34 ,  A61K39/095 ,  C07K14/315 ,  C07K14/22

Abstract: The present disclosure relates generally to methods of preparing glycoconjugates containing a saccharide conjugated to a carrier protein by use of stable nitroxyl radical related agent/oxidant as an oxidizing agent, to immunogenic compositions comprising such glycoconjugates, and to methods for the use of such glycoconjugates and immunogenic compositions.

公开(公告)号：US20180099039A1

公开(公告)日：2018-04-12

申请号：US15286696

申请日：2016-10-06

Applicant: Pfizer Inc.

Inventor： Emilio Anthony Emini ,  Wendy Jo Watson ,  Avvari Krishna Prasad ,  Mingming Han ,  Jin-Hwan Kim ,  Jianxin Gu ,  Yu-ying Yang ,  Rajesh Kumar Kainthan ,  David Cooper ,  Michael William Pride ,  Kathrin Ute Jansen

IPC: A61K39/09 ,  A61K9/19

CPC classification number: A61K39/092 ,  A61K47/646 ,  A61K2039/55505 ,  A61K2039/6037 ,  A61K2039/70 ,  Y02A50/466

Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.

公开(公告)号：US11872274B2

公开(公告)日：2024-01-16

申请号：US17194224

申请日：2021-03-06

Applicant: Pfizer Inc.

Inventor： Emilio Anthony Emini ,  Wendy Jo Watson ,  Avvari Krishna Prasad ,  Mingming Han ,  Jin-Hwan Kim ,  Jianxin Gu ,  Yu-Ying Yang ,  Rajesh Kumar Kainthan ,  David Cooper ,  Michael William Pride ,  Kathrin Ute Jansen

IPC: A61K39/00 ,  A61K39/09 ,  A61K47/64

CPC classification number: A61K39/092 ,  A61K47/646 ,  A61K2039/55505 ,  A61K2039/6037 ,  A61K2039/70 ,  Y02A50/30

Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.

公开(公告)号：US20230203091A1

公开(公告)日：2023-06-29

申请号：US18176631

申请日：2023-03-01

Applicant: Pfizer Inc.

Inventor： Mingming Han ,  Rajesh Kumar Kainthan ,  Jin-Hwan Kim ,  Avvari Krishna Prasad

IPC: C07K1/107 ,  C07K14/34 ,  C07K14/22 ,  C07K14/315 ,  A61K39/095 ,  A61K39/09 ,  A61K47/64 ,  C07H3/06

CPC classification number: C07K1/1077 ,  C07K14/34 ,  C07K14/22 ,  C07K14/315 ,  A61K39/095 ,  A61K39/092 ,  A61K47/646 ,  A61K47/6415 ,  A61K39/09 ,  C07H3/06 ,  A61K2039/6037

Abstract: The present disclosure relates generally to methods of preparing glycoconjugates containing a saccharide conjugated to a carrier protein by use of stable nitroxyl radical related agent/oxidant as an oxidizing agent, to immunogenic compositions comprising such glycoconjugates, and to methods for the use of such glycoconjugates and immunogenic compositions.

公开(公告)号：US11426456B2

公开(公告)日：2022-08-30

申请号：US17060337

申请日：2020-10-01

Applicant: Pfizer Inc.

Inventor： Jianxin Gu ,  Rajesh Kumar Kainthan ,  Jin-Hwan Kim ,  Avvari Krishna Prasad ,  Yu-Ying Yang

IPC: A61K39/09 ,  A61K39/385 ,  A61K39/39 ,  A61K39/00

Abstract: The invention relates to activated Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides and processes for their preparation. The invention also relates to immunogenic conjugates comprising Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides covalently linked to a carrier protein, processes for their preparation and immunogenic compositions and vaccines comprising them.

公开(公告)号：US20210196810A1

公开(公告)日：2021-07-01

申请号：US17194224

申请日：2021-03-06

Applicant: Pfizer Inc.

Inventor： Emilio Anthony Emini ,  Wendy Jo Watson ,  Avvari Krishna Prasad ,  Mingming Han ,  Jin-Hwan Kim ,  Jianxin Gu ,  Yu-ying Yang ,  Rajesh Kumar Kainthan ,  David Cooper ,  Michael William Pride ,  Kathrin Ute Jansen

IPC: A61K39/09 ,  A61K47/64

Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.

公开(公告)号：US10946086B2

公开(公告)日：2021-03-16

申请号：US16245378

申请日：2019-01-11

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Amardeep Singh Bhupender Bhalla ,  Robert G. K. Donald ,  Jianxin Gu ,  Kathrin Ute Jansen ,  Rajesh Kumar Kainthan ,  Lakshmi Khandke ,  Jin-Hwan Kim ,  Paul Liberator ,  Avvari Krishna Prasad ,  Mark Edward Ruppen ,  Ingrid Lea Scully ,  Suddham Singh ,  Cindy Xudong Yang

IPC: A61K39/09 ,  A61K39/39 ,  A61K39/40 ,  A61K39/00 ,  C07K16/12 ,  C07K16/44 ,  A61K47/10 ,  A61K47/26

Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

公开(公告)号：US20200306357A1

公开(公告)日：2020-10-01

申请号：US16899738

申请日：2020-06-12

Applicant: Pfizer Inc.

Inventor： Emilio Anthony Emini ,  Wendy Jo Watson ,  Avvari Krishna Prasad ,  Mingming Han ,  Jin-Hwan Kim ,  Jianxin Gu ,  Yu-ying Yang ,  Rajesh Kumar Kainthan ,  David Cooper ,  Michael William Pride ,  Kathrin Ute Jansen

IPC: A61K39/09 ,  A61K47/64

Abstract: The present invention relates to new immunogenic compositions comprising conjughated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.